NASDAQ:EBIO - Eleven Biotherapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$2.65Today's Range$2.73 - $3.4452-Week Range$0.62 - $3.50Volume15.58 million shsAverage Volume2.86 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company's targeted therapeutic, Vicinium in combination with AstraZeneca's immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts. Receive EBIO News and Ratings via Email Sign-up to receive the latest news and ratings for EBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EBIO Previous Symbol CUSIPN/A Webwww.elevenbio.com Phone617-871-9911Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees17 Outstanding SharesN/AMarket Cap$0.00 OptionableOptionable Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions What is Eleven Biotherapeutics' stock symbol? Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO." How were Eleven Biotherapeutics' earnings last quarter? Eleven Biotherapeutics (NASDAQ:EBIO) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History. What price target have analysts set for EBIO? 2 equities research analysts have issued twelve-month price objectives for Eleven Biotherapeutics' shares. Their predictions range from $2.00 to $8.00. On average, they anticipate Eleven Biotherapeutics' share price to reach $5.00 in the next twelve months. View Analyst Price Targets for Eleven Biotherapeutics. What is the consensus analysts' recommendation for Eleven Biotherapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eleven Biotherapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eleven Biotherapeutics. Has Eleven Biotherapeutics been receiving favorable news coverage? Media stories about EBIO stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eleven Biotherapeutics earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term. Who are some of Eleven Biotherapeutics' key competitors? Some companies that are related to Eleven Biotherapeutics include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO) and Egalet (EGLT). Who are Eleven Biotherapeutics' key executives? Eleven Biotherapeutics' management team includes the folowing people: Mr. Stephen A. Hurly, Pres, CEO & Director (Age 50)Dr. K. Christopher Garcia, Co-Founder and Member of Scientific Advisory BoardDr. Gregory L. Verdine, Co-Founder (Age 59)Dr. Karl Dane Wittrup Ph.D., Co-Founder and Member of Scientific Advisory BoardDr. Reza Dana M.D., MPH,M.Sc, Founder and Member of Scientific Advisory Board How do I buy shares of Eleven Biotherapeutics? Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eleven Biotherapeutics' official website? The official website for Eleven Biotherapeutics is http://www.elevenbio.com. How can I contact Eleven Biotherapeutics? Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected] MarketBeat Community Rating for Eleven Biotherapeutics (NASDAQ EBIO)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 118 (Vote Outperform)Underperform Votes: 117 (Vote Underperform)Total Votes: 235MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe EBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: What is the quiet period?